Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever

Trabulus S., Korkmaz M., Kaya E., Seyahi N.

CLINICAL TRANSPLANTATION, vol.32, no.8, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 8
  • Publication Date: 2018
  • Doi Number: 10.1111/ctr.13345
  • Journal Name: CLINICAL TRANSPLANTATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Istanbul University Affiliated: Yes

Abstract

Background: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent serosal inflammation with fever, which can result in amyloid deposition. Anti-interleukin-1 drugs emerge as a therapeutic option for colchicine-resistant patients. In this study, we aimed to document our experience with canakinumab use in kidney transplant recipients who developed AA amyloidosis due to FMF.